Abstract: Disclosed are compounds of the formula in free or salt form, wherein X, R1, R2, R3, and R4 are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of inflammatory or obstructive airways disease.

Abstract: A synthesis member preferably comprises two elements: a crown and a stem. The stem includes a tag, such as a transponder, that is used to identify the synthesis member and/or the synthetic history of the synthesis member when used in the automated synthesis of compound libraries containing large numbers (e.g. 1000 or more) compounds. The crown provides the location at which compounds are synthesized. The combination of a crown for use with compound synthesis and stem allows the tracking of individual synthesis members from a library containing thousands of such synthesis members. Because each synthesis member is individually tracked and can be logged into a database and/or process flow control system, the synthesis of several thousand individual compounds in conventional containers, such as round bottom flasks is made possible using only traditional compound synthesis approaches.

Abstract: Use of a compound of formula I wherein R1 is a C1-4 alkoxy or thioalkoxy group, and R2 is a group of formula SR10 or OR10 wherein R10 is a C1-4 carboxylic or thiocarboxylic acid residue in salt, ester, free acid or activated form, or an activated form thereof, as a linker in solid phase synthesis of organic compounds, preferably of carbamates and secondary amines, and in addition are provided processes, solid phase systems and intermediates based on the compound of formula I.

Abstract: Compounds of formulaA--X--Y--NH--Bwherein A is derived from optionally substituted benzothiophene, indole, 4-aza-and 7-aza-benzothiophene or-indole, A bearing in position 5 hydrogen, halogen, optionally substituted alkyl, hydroxy, nitro, amino, alkylamino, acylamino, alkoxycarbonyl, sulfamoyl, cyano, trimethylsilyl, carboxy, carbamoyl, phosphate, oxycarbamoyl, heterocyclic radical or ether or ester group, X-Y is --CR.sub.8 .dbd.N-- or CH(R.sub.8)--NH-- wherein R.sub.8 is -H or alkyl and attached at position 3 of A, and B is a heterocyclic radical or a residue ##STR1## wherein R.sub.10 is H, optionally substituted alkyl, cycloalkyl, aryl, adamantyl, acyl or carbamoyl and X.sub.2 is alkylthio or NR.sub.3 R.sub.10 wherein R.sub.3 is H or alkyl or R.sub.3 and R.sub.10 together with the nitrogen atom to which they are attached form a heterocyclic radical, in free form or in salt form, have pharmacological activity, e.g. for treating gastrointestinal disorders.